See What HealthDay Can Do For You
Contact Us

Contrast-Enhanced Ultrasound No Aid for Metastasis Detection

Findings based on use of laparoscopic ultrasonography during colorectal cancer surgery

digestive system

FRIDAY, Dec. 15, 2017 (HealthDay News) -- Contrast-enhanced laparoscopic ultrasonography (CE-LUS) does not appear to increase the detection rate of liver metastasis during robotic-assisted surgery for primary colorectal cancer (CRC), according to a study published online Nov. 13 in the Journal of Clinical Ultrasound.

Signe Bremholm Ellebæk, M.D., from Odense University Hospital in Denmark, and colleagues assessed the potential clinical value of CE-LUS as a screening tool for liver metastases during robotic-assisted surgery for primary CRC among 50 consecutive patients.

The researchers found that patients were equally distributed between stage I, II, and III classification. CE-LUS did not detect any liver metastasis, as was confirmed by follow-up using contrast-enhanced computed tomography imaging at three and 12 months postoperatively. CE-LUS was easy to perform and no complications were reported.

"The use of CE-LUS as a screening modality for detection of liver metastasis cannot be recommended based on this study, but larger controlled studies on high-risk patients seem relevant," the authors write.

Abstract
Full Text (subscription or payment may be required)

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.